Impact of rituximab trials on the treatment of ANCA-associated vasculitis. - Wikidata - wikimedia - TriplyDB

Impact of rituximab trials on the treatment of ANCA-associated vasculitis.

Impact of rituximab trials on the treatment of ANCA-associated vasculitis.

http://www.wikidata.org/entity/Q38152651

about

Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis Atypical Endobronchial Carcinoid with Postobstructive Pneumonia Obscuring the Diagnosis of Granulomatosis with Polyangiitis Genetic aspects of anti-neutrophil cytoplasmic antibody-associated vasculitis.Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?Rituximab as an alternative for patients with severe systemic vasculitis refractory to conventional therapy: report of seven cases and literature review.Lupus nephritis and B-cell targeting therapy.Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis.Rituximab for treatment of severe renal disease in ANCA associated vasculitis.Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.Rituximab in refractory sarcoidosis: a single centre experience.Brief Report: Rituximab for the Treatment of Adult-Onset IgA Vasculitis (Henoch-Schönlein)."Exercise induced asthma" is not always asthma.

P2860

Q35759180-DC796DD3-77E7-44A0-9230-FFD95A51E5DA Q35992340-685E0B53-BBCF-45BE-9F23-131C5469E06B Q38293706-13000423-AEF4-4036-B63E-37F663E031E4 Q38543360-53B37875-DD7C-41C8-A8D1-2C3EDDC1DAC8 Q38576072-50D3746D-40A3-4134-9ADE-834D18CD7661 Q38643755-1FB62598-5468-4BDA-99DC-8DCF942F1208 Q40075352-5435DB4A-9CDB-4B16-B879-1063B9ACD0E3 Q40927033-DB33B31A-1AB0-4459-805D-C91D45C5BF1C Q41208157-EBC807B8-25E3-4E94-BF8D-3CBF469AD5C6 Q42706595-7036FBF2-EC65-40EA-9A2E-F08C49F211BD Q43013396-564C7879-C73F-4580-BB31-B86D385CC1A4 Q47705620-8B851A06-55CE-43FD-A926-02CD1091E582 Q55491883-A8CE5C01-A4B5-4498-B6C2-1E4A09859BA7

P2860

Impact of rituximab trials on the treatment of ANCA-associated vasculitis.

http://www.wikidata.org/entity/Q38152651

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Impact of rituximab trials on the treatment of ANCA-associated vasculitis.

@en

type

label

Impact of rituximab trials on the treatment of ANCA-associated vasculitis.

@en

prefLabel

Impact of rituximab trials on the treatment of ANCA-associated vasculitis.

@en

P1433

Q38152651-501D9073-6BDF-4DE9-AACF-209A6590412B

P1476

Q38152651-799988AC-5A7F-4246-AA3F-7171E5DC319C

P2093

Q38152651-94EA7BBE-2C8E-4918-8539-29985650A41F

P2860

Q38152651-0295AFB8-4D1C-4995-A4D7-8B49DD910F8E

Q38152651-055A5254-F0A2-4D62-9A0C-C1F89284DF0F

Q38152651-0808C001-1192-45EB-A01A-9BA0150E25C1

Q38152651-0A075A3F-0DD8-4FED-BAC3-1C00CE73C8CF

Q38152651-0F6964F0-E411-4408-9D1B-356EA20BD308

Q38152651-158C4112-E2F0-4B1C-81C6-77C6C551AB7F

Q38152651-16CAD651-178F-4F9C-9C51-0CF27D1A0597

Q38152651-17EEC671-2204-404C-ABA0-641EF300C683

Q38152651-1B5CA0A6-BE81-4D85-B73B-3E106AEB60E6

Q38152651-20876EEB-D754-4512-ABDE-51F10135988F

P304

Q38152651-E484D48F-468D-4333-A6D7-BCAB0E452FCF

P31

Q38152651-2F6A1107-6065-4DB8-8C66-4FBBC9E4929C

P356

Q38152651-E4B816D1-0B76-4D8C-94FB-A0A9EDE9268A

P407

Q38152651-DE63489D-8471-4FCA-AAC8-D7BCF4C0F5E8

P433

Q38152651-8B3A8060-C0F8-4252-8C72-EA9C55E9BA94

P478

Q38152651-906312A4-E0CA-4EC4-8919-6A2E421E9634

P50

Q38152651-6BD9AFF3-1675-4152-A796-D86018D317EF

P577

Q38152651-D934D097-9CB1-438B-B84E-B35C7C399588

P5875

Q38152651-5802BA10-1217-4821-A25F-9AFF5C17FB23

P698

Q38152651-D36B8A57-936D-4FEC-8D33-13695F742693

P356

P1433

Nephrology Dialysis Transplantation

P1476

Impact of rituximab trials on the treatment of ANCA-associated vasculitis.

@en

P2093

David R W Jayne

http://www.w3.org/2001/XMLSchema#string

P2860

Rituximab: mechanism of action

Genetically distinct subsets within ANCA-associated vasculitis

Nomenclature of systemic vasculitides. Proposal of an international consensus conference

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.

Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis

Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.

Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis.

From T to B and back again: positive feedback in systemic autoimmune disease.

P304

1151-1159

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFT318

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257814348

http://www.w3.org/2001/XMLSchema#string

P698

24126571

http://www.w3.org/2001/XMLSchema#string